Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study
Rattachement africain : cn, gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Adding daratumumab to initial therapy in randomized controlled trials (RCTs) for newly diagnosed multiple myeloma (MM) enhances deep remission and prolongs progression-free survival (PFS). Given the differences between trial-eligible and real-world patients, and healthcare access variability in developing countries, real-world data are essential to complement RCT evidence. METHODS: We analyzed 761 newly diagnosed MM patients treated with (n = 177) or without (n = 584) daratumumab as first-line therapy from 2017 to 2023 across southern China. Propensity score matching (PSM) generated cohorts of 158 and 278 patients, respectively, matched for stage, cytogenetic abnormalities, and regimen type. Responses were evaluated per International Myeloma Working Group criteria, and measurable residual disease (MRD) was assessed via next-generation multiparameter flow cytometry. RESULTS: The daratumumab group demonstrated significantly higher rates of ≥ very good partial response (85.0% vs. 61.3%; P < 0.001) and MRD negativity (73.0% vs. 51.9%; P = 0.024) at the end of induction. Additionally, 3-year PFS (75.6% vs. 55.0%, hazard ratio [HR] 0.49, 95% confidence interval [95% CI] 0.36-0.66, P < 0.001) and overall survival (OS) rates (78.3% vs. 74.4%; HR 0.56 [95% CI 0.36-0.86], P = 0.008) were superior in the daratumumab group, and these results remained consistent after PSM. Daratumumab improved PFS in patients with gain/amp(1q21) but not in those with del17p or t(4;14). Survival benefit was also observed in the addition of daratumumab to bortezomib/lenalidomide/dexamethasone combined treatment subgroup. CONCLUSION: In real-world settings, daratumumab-based first-line therapy improved the depth of response, PFS, and OS, though not all patients benefited.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study
- Date Crossref
- 05/02/2026
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Sun Yat-sen University Department of Hematologic Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Sun Yat-sen University Cancer Center pays non établi dans la noticeÉtablissement de santé
-
First Affiliated Hospital of GuangXi Medical University Department of Hematology pays non établi dans la noticeÉtablissement de santé
-
Nanfang Hospital pays non établi dans la noticeÉtablissement de santé
-
Southern Medical University Department of Hematology pays non établi dans la noticeUniversité ou école supérieure
-
Hainan Medical College Hospital pays non établi dans la noticeÉtablissement de santé
-
Shenzhen Second People's Hospital Department of Hematology pays non établi dans la noticeÉtablissement de santé
-
First Affiliated Hospital of Guangzhou Medical University Department of Hematology pays non établi dans la noticeÉtablissement de santé
-
Guangzhou Medical University pays non établi dans la noticeUniversité ou école supérieure
-
Zhuzhou Central Hospital Department of Hematology pays non établi dans la noticeÉtablissement de santé
-
Hainan General Hospital Department of Hematology pays non établi dans la noticeÉtablissement de santé
-
Hainan Medical University Department of Hematology pays non établi dans la noticeUniversité ou école supérieure
Department of Hematologic Oncology — Sun Yat-sen University, Sun Yat-sen University Cancer Center et Department of Hematology — First Affiliated Hospital of GuangXi Medical University, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.